Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
ARMP
ARMP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest ARMP ETF News Today | Earnings, Events & Price Alerts
ARMP News
Significant Milestones in Biotech Sector This Week
4d ago
NASDAQ.COM
Armata Receives FDA QIDP Designation for Staphylococcus aureus Treatment
Feb 23 2026
Newsfilter
Armata Pharmaceuticals' AP-SA02 Advances to Phase 3 Clinical Study Following Positive FDA Feedback
Jan 13 2026
NASDAQ.COM
Armata Pharmaceuticals' AP-SA02 Advances to Phase 3 Clinical Trial Following FDA Approval
Jan 13 2026
PRnewswire
Armata Pharmaceuticals' AP-SA02 Advances to Phase 3 Clinical Study with FDA Support
Jan 13 2026
Newsfilter
Coherus Oncology (CHRS) Posts Q3 Loss and Falls Short of Revenue Projections
Nov 07 2025
NASDAQ.COM
Armata Pharmaceuticals (ARMP) Soars 103.2%: Could This Signal More Upside Ahead?
Oct 23 2025
NASDAQ.COM
Reasons Behind the 300% Surge in Armata Pharmaceuticals Stock (ARMP) Today
Oct 22 2025
TipRanks
Armata Rises Following Mid-Stage Trial Results for Antibacterial Drug
Oct 22 2025
SeekingAlpha
Armata Pharmaceuticals Reveals Publication on Structural Biology in the Journal of Molecular Biology
Sep 08 2025
Newsfilter
All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy
Aug 15 2025
NASDAQ.COM
Armata Posts 59 Percent Q2 Revenue Jump
Aug 13 2025
NASDAQ.COM
Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates
Aug 12 2025
NASDAQ.COM
HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Raises Price Target to $9
May 19 2025
Benzinga
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
May 19 2025
Newsfilter
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
May 12 2025
NASDAQ.COM
Show More News
